卒中发病前服用直接口服抗凝药患者的静脉溶栓:卒中治疗安全实施国际卒中登记研究结果
该观察性登记研究分析2013—2024年SITS国际卒中溶栓登记数据,比较发病前服用DOAC与未服用OAC的急性缺血性卒中患者静脉溶栓的安全性和结局。倾向评分匹配后,DOAC组894例与无OAC组1788例在症状性颅内出血、3个月功能独立和死亡方面均无显著差异。
要点
- 发病前服用DOAC的急性缺血性卒中患者接受静脉溶栓,症状性颅内出血比例与未服用OAC者相似。
- 匹配后DOAC组与无OAC组3个月功能独立和死亡比例均无显著差异。
- 末次DOAC服药至静脉溶栓的时间间隔未影响结局。
核心结论
- 在这项观察性研究中,发病前服用DOAC的急性缺血性卒中患者接受静脉溶栓后结局与未服用OAC治疗的患者相比未发现任何差异。
研究设计与样本
- 分析2013—2024年卒中治疗安全实施(SITS)国际卒中溶栓登记研究数据。
- 共纳入1311例DOAC患者和129384例无OAC患者。
- 采用最近邻匹配算法按1:2比例进行倾向评分匹配,匹配894例DOAC患者与1788例无OAC患者。
- 匹配后DOAC组平均年龄75岁 vs 无OAC组76岁,美国国立卫生研究院卒中量表评分中位数11 vs 12。
主要发现
- DOAC组 vs 无OAC组:SITS监测研究定义的症状性颅内出血1.1% vs 1.5%(p=0.50)。
- DOAC组 vs 无OAC组:欧洲急性卒中协作研究II定义的症状性颅内出血4.0% vs 4.3%(p=0.82)。
- DOAC组 vs 无OAC组:任何脑实质血肿6.3% vs 7.8%(p=0.22)。
- DOAC组 vs 无OAC组:3个月功能独立(改良Rankin量表评分0-2)47.9% vs 46.4%(p=0.59)。
- DOAC组 vs 无OAC组:3个月死亡25.1% vs 24.0%(p=0.65);末次DOAC服药至静脉溶栓时间未影响结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Intravenous thrombolysis (IVT) is contraindicated for acute ischemic stroke (AIS) patients taking direct oral anticoagulants (DOACs) within 48 hours before index stroke. Limited data exist on off-label use of IVT for these patients. We compared the safety and outcomes of IVT in AIS patients with DOAC treatment and patients with no OAC before index stroke. METHODS: We analyzed data from the Safe Implementations of Treatments in Stroke (SITS) International Stroke Thrombolysis Registry during 2013-2024. Outcomes were symptomatic intracerebral hemorrhage (SICH) by the SITS Monitoring Study and European Cooperative Acute Stroke Study II definitions, functional independency (modified Rankin Scale score 0-2), and death by 3 months. Propensity score matching with a nearest neighbor matching algorithm with a ratio of 1:2 was used for relevant clinical variables. We also analyzed the time from last DOAC dose to IVT treatment. RESULTS: A total of 1,311 DOAC and 129,384 no OAC patients were included. We matched 894 patients with DOAC to 1,788 with no OAC. The mean age was 75 years versus 76 years, and the median National Institutes of Health Stroke Scale score 11 versus 12, respectively. Patients with DOAC had a similar proportion of outcomes compared with patients with no OAC: SICH per SITS Monitoring Study (1.1 vs 1.5%, p = 0.50), SICH per European Cooperative Acute Stroke Study II (4.0 vs 4.3%, p = 0.82), any parenchymal hematoma (6.3 vs 7.8, p = 0.22), and functional independency (47.9 vs 46.4%, p = 0.59) and death (25.1 vs 24.0%, p = 0.65) at 3-month follow-up. The time from last DOAC dose to IVT did not affect outcomes. INTERPRETATION: In this observational study, we did not find any difference in outcomes after IVT therapy in AIS patients with DOAC compared with no OAC treatment before index stroke. ANN NEUROL 2025;97:1205-1214.
引用
- Matusevicius M, Säflund M, Balestrino M, et al. Intravenous Thrombolysis in Patients Taking Direct Oral Anticoagulation Treatment Before Stroke Onset: Results from the Safe Implementations of Treatments in Stroke International Stroke Registry. Ann Neurol. 2025. PMID: 39902556. doi:10.1002/ana.27189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。